FDA Accepts Bristol Myers Squibb's NDA for Iberdomide with Priority Review

The FDA has accepted Bristol Myers Squibb's New Drug Application (NDA) for Iberdomide, granting it Priority Review status. This indicates the agency's expedited review of the drug.